Clinical trials: Influenza in Humans
Influenza
Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules
Today, the leading contender for the next influenza pandemic is H5N1, a strain of avian virus found primarily in domestic and wild birds. Experts warn that the next influenza pandemic is imminent and could be severe.
- Trial name
- NCT00652743
- Testing
- Pandemic influenza vaccine GSK1562902A
- Where
- 6 sites in Hong Kong, Singapore and 2 more
- Volunteers
- 845 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
ARDS, Covid19
Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS
This is a randomized, double-blinded, placebo-controlled study of AVM0703 administered as a single intravenous (IV) infusion to patients with moderate or severe immediately life-threatening Acute Respiratory Distress Syndrome…
- Conditions
- ARDS, Covid19, Influenza, Human
- Trial name
- AVM0703 (NCT04366115)
- Testing
- AVM0703
- Volunteers
- 16 people
- Sponsor
- AVM Biotechnology Inc
Influenza
Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine
The purpose of the study is to determine the amount of live virus that can be recovered from the nose of people who are vaccinated with the licensed live vaccine against H1N1, and to describe the immune response to vaccination.
- Trial name
- NCT01023776
- Testing
- A/California/07/09 live monovalent H1N1 vaccine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Influenza
The Objectives of This Study Are Study the Safety, Reactogenicity and Obtain Preliminary Data on the Immunogenicity of Flu-M Quadro, 4-valent Inactivated Split Influenza Vaccine, in Healthy Volunteers
The study the safety, reactogenicity and obtain preliminary data on the immunogenicity of Flu-M Quadro, 4-valent inactivated split influenza vaccine, in healthy volunteers
- Trial name
- NCT05152017
- Testing
- Flu-M Quadro [inactivated split influenza vaccine] with preservative, Flu-M Quadro [inactivated split influenza vaccine] without preservative
- Where
- Russia
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- St. Petersburg Research Institute of Vaccines and Sera
Influenza
Evaluation of Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Years and Older
The purpose of this study is to evaluate the safety and immunogenicity of GlaxoSmithKline Biologicals' influenza vaccine GSK2186877A in adults 65 year of age and older.
- Trial name
- NCT00760617
- Testing
- GSK Bio's influenza vaccine GSK2186877A, Fluarix
- Where
- 25 sites in Germany, Netherlands and 1 more
- Volunteers
- 526 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity of Adjuvanted or Non-adjuvanted H5N1 Booster Vaccine in Adults Primed to A/VN/1194/04
This study focuses on pre-pandemic priming of man against H5 influenza with the goal of mounting a robust antibody response to small quantities of vaccine either before or during an H5 pandemic.
- Trial name
- NCT00814385
- Testing
- Aflunov (Single prime, single boost), Aflunov (Double prime, single boost), Aflunov (No prime, single boost)
- Where
- 2 sites in United Kingdom
- Volunteers
- 606 people, healthy volunteers welcome
- Sponsor
- University Hospitals, Leicester
Influenza, Human
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of QIVc in Subjects ≥2 to <18 Years of Age
This Phase 3/4, randomized, observer-blind, multi-center study, stratified study evaluated the immune (antibody) response, efficacy and safety of a cell-derived quadrivalent subunit influenza virus vaccine (Seqirus QIVc) in…
- Trial name
- NCT03165617
- Testing
- QIVc, Non-influenza Comparator Vaccine
- Where
- 40 sites in Australia, Estonia and 6 more
- Volunteers
- 4,514 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
Study on the Immunogenicity and Tolerability of Influsplit SSW® 2005/2006 in Children Aged 6 - 13 Years
The study will evaluate the immune response and the tolerability of the influenza vaccine administered in children aged 6-13 years old.
- Trial name
- NCT00372255
- Testing
- Influsplit SSW® 2005/2006
- Where
- 18 sites in Germany
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Respiratory Viral Infection
Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle
This study will evaluate a home-based approach to influenza infection control, using prepositioned home-based influenza self-test kits, telemedicine services, and rapid delivery of Xofluza (Baloxavir marboxil) for administration…
- Trial name
- pCHIMES (NCT04141930)
- Testing
- Baloxavir Marboxil
- Where
- United States
- Volunteers
- 481 people, healthy volunteers welcome
- Sponsor
- University of Washington
Swine-Origin Influenza A H1N1 Virus
Open-label, Uncontrolled Postmarketing Study of Cell-derived A/H1N1 Influenza HA Vaccine in Japanese Elderly Subjects
This is to evaluate immunogenicity based on EMEA/CHMP criteria, and safety \& tolerability of cell-derived A/H1N1 influenza HA vaccine in healthy Japanese elderly subjects.
- Trial name
- NCT01069367
- Testing
- Emulsion, Cell Culture-based, influenza HA vaccine H1N1
- Where
- Japan
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months
This study will evaluate the safety and immunogenicity of different combinations of A/H1N1 2009 (swine flu) vaccine in healthy young children
- Trial name
- NCT00996307
- Testing
- MF59-eH1N1_f
- Where
- 29 sites in United States, Mexico
- Volunteers
- 654 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Childhood Influenza Vaccination, School-located Influenza Vaccination
School-located Influenza Vaccination Clinics for Adolescents
A cluster-randomized trial (clustering by school) was conducted in Monroe County, NY. Twenty middle and high schools were paired based on several characteristics and randomized within pairs to receiving a school-based influenza…
- Trial name
- SKIPP RCT2 (NCT03137667)
- Testing
- School-located Influenza Vaccination
- Volunteers
- 17,650 people
- Sponsor
- University of California, Los Angeles
Influenza Vaccines Efficacy and Safety
Efficacy & Safety of Nasal Influenza Immunisation in Children
The UK Departments of Health now recommend annual influenza vaccination for all children 2-7 years of age, with children over 7 years eligible for vaccination if in certain higher risk clinical categories.
- Trial name
- SNIFFLE-3 (NCT02549365)
- Testing
- Live attenuated influenza vaccine, Surveillance (nasal swabbing) during influenza season
- Where
- United Kingdom
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Influenza
A Comparison of One Versus Two Doses of Influenza Vaccine in Children 5-8 Years of Age
The purpose of the study was to find out if children 5 through 8 years of age who are getting influenza vaccine for the first time should get one or two doses.
- Trial name
- NCT00158665
- Testing
- 2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine
- Where
- United States
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Kaiser Permanente
Immune Response
Agaricus Bisporus and Influenza Vaccination Response
There are numerous in vitro and animal studies that suggested that mushrooms beneficially influence the immune system. We have recently shown that a wild isolate of the edible Agaricus bisporus mushroom had a clear effect on…
- Trial name
- NCT06041867
- Testing
- Influenza vaccine, Agaricus bisporus capsules, Control capsules
- Where
- Netherlands
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Maastricht University Medical Center
Influenza, Immunosuppression
High Dose vs. Standard Influenza Vaccine in Adult SOT
The study will test whether a high dose influenza vaccination results in improved immunogenicity in adult SOT recipients as compared to standard vaccine.
- Trial name
- NCT03139565
- Testing
- Fluzone High-dose Influenza Vaccine, Standard 2016-2017 Flu vaccine
- Where
- Canada
- Volunteers
- 172 people
- Sponsor
- University Health Network, Toronto
Avian Influenza, Influenza Immunisation
2013/2017 H7N9 Prime-Boost Interval
This is a trial designed to assess the safety, reactogenicity and immunogenicity of one or two doses of monovalent inactivated split influenza 2013 and 2017 A/H7N9 virus vaccines administered intramuscularly at different dosages…
- Trial name
- NCT03589807
- Testing
- A/H7N9, AS03, Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013
- Where
- 6 sites in United States
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infectious Disease, Influenza
Antibiotic Therapy in Viral Airway Infections
Antimicrobial resistance is one of the most urgent health threats of our time, and Norwegian hospitals were required to reduce the use of broad-spectrum antibiotics with 30% by the end of 2020.
- Conditions
- Infectious Disease, Influenza, Respiratory Syncytial Virus (RSV), Respiratory Tract Infections
- Trial name
- ATHENIAN (NCT05045612)
- Testing
- Stop antibiotic therapy
- Where
- 12 sites in Norway
- Volunteers
- 380 people
- Sponsor
- University Hospital, Akershus
Influenza
H7N9 Boost in Healthy Adults
The study will be an open-label phase 2 clinical trial of a single dose of an inactivated H7N9 influenza vaccine (non-adjuvanted).
- Trial name
- NCT02586792
- Testing
- Monovalent influenza A/H7N9 virus vaccine
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Healthy Volunteers
Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older
VAM00001 is a Phase I/II, randomized, modified double-blind, multi-center study. The purpose of this study is to compare 2 dose levels of Panblok H7 (dose 1 and dose 2 of rHA) with a standard squalene dose of adjuvant MF59 to…
- Trial name
- NCT05608005
- Testing
- Panblok + MF59 Dose 1, Panblok + MF59 Dose 2, Unadjuvanted Panblok Dose 3
- Where
- 16 sites in United States
- Volunteers
- 581 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company